FY2025 EPS Estimates for Danaher Lowered by Leerink Partnrs

Key Points

• Leerink Partners has lowered their FY2025 earnings estimate for Danaher to $7.70 per share, down from a previous forecast of $7.76, while the current consensus is at $7.63.
• Danaher reported $1.89 EPS for the latest quarter, exceeding the consensus estimate of $1.72, with revenue growing 4.4% year-over-year to $6.05 billion.
• The company declared a quarterly dividend of $0.32 per share, reflecting a dividend yield of 0.6%, with an annual payout totaling $1.28.

Danaher Corporation (NYSE:DHR - Free Report) - Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for Danaher in a report released on Tuesday, October 21st. Leerink Partnrs analyst P. Souda now expects that the conglomerate will earn $7.70 per share for the year, down from their previous forecast of $7.76. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. Leerink Partnrs also issued estimates for Danaher's Q4 2025 earnings at $2.13 EPS, Q1 2026 earnings at $2.10 EPS, Q4 2026 earnings at $2.35 EPS and FY2026 earnings at $8.35 EPS.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.93%. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The company's revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS.

Several other brokerages also recently commented on DHR. Rothschild Redb downgraded shares of Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 8th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Danaher in a research note on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Robert W. Baird set a $247.00 price target on shares of Danaher in a research note on Wednesday. Finally, Cowen reissued a "buy" rating on shares of Danaher in a research note on Wednesday. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $243.39.

Danaher Stock Performance

NYSE DHR opened at $218.06 on Thursday. The company has a 50-day simple moving average of $202.24 and a two-hundred day simple moving average of $197.73. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher has a 12-month low of $171.00 and a 12-month high of $260.88. The firm has a market cap of $156.14 billion, a price-to-earnings ratio of 44.96, a PEG ratio of 3.20 and a beta of 0.77.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio is presently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

Large investors have recently bought and sold shares of the business. White Pine Capital LLC lifted its stake in shares of Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate's stock worth $690,000 after purchasing an additional 49 shares during the last quarter. Boyd Watterson Asset Management LLC OH lifted its stake in shares of Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate's stock worth $499,000 after purchasing an additional 51 shares during the last quarter. Hills Bank & Trust Co lifted its stake in shares of Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after purchasing an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC lifted its stake in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock worth $236,000 after purchasing an additional 53 shares during the last quarter. Finally, Howard Capital Management Group LLC lifted its stake in shares of Danaher by 4.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate's stock worth $230,000 after purchasing an additional 53 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.